Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
Onco Targets Ther
; 9: 4843-58, 2016.
Article
in En
| MEDLINE
| ID: mdl-27540299
ABSTRACT
The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more targeted therapeutic approaches. Several new drugs with novel mechanism of action and less toxic profile have been developed in the past decade, with the potential for use as single agents or in synergy with other treatment modalities in MM therapy. As our discovery of these emerging therapies progresses, so too does our need to reshape our knowledge on knowing how to apply them. This review highlights some of the recent landmark changes in MM management with specific emphasis on salvage drugs available for relapsed and refractory MM and also discusses some of the upcoming cutting-edge therapies that are currently in various stages of clinical development.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Onco Targets Ther
Year:
2016
Document type:
Article